emrah gün

Dr. emrah gün

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Primary Care Diabetes
Verified
Journal Article
Closed access
EGemrah gün
emrah gün
HUHakan Uzun
Hakan Uzun
SBSemih Bolu
Semih Bolu
IAIlknur Arslanoglu
Ilknur Arslanoglu
KKKenan Kocabay
Kenan Kocabay

11 November 2022 in Acute and Critical Care
Verified
Journal Article
Open access
PDF file
EBEdin Botan
Edin Botan
EGemrah gün
emrah gün
EŞEmine Kübra Şen
Emine Kübra Şen
CYCansu Yöndem
Cansu Yöndem
AGAnar Gurbanov
Anar Gurbanov
TKTANIL KENDIRLI
TANIL KENDIRLI
Background: Pediatric intensive care units (PICUs), where children with critical illnesses are treated, require considerable manpower and technological infrastructure in order to keep children alive and free from sequelae. Methods: In this retrospective comparative cohort study, hospital records of patients aged 1 month to 18 years who died in the study PICU between January 2015 and December 2019 were reviewed. Results: A total of 2,781 critically ill children were admitted to the PICU. The mean±standard deviation age of 254 nonsurvivors was 64.34±69.48 months. The mean PICU length of stay was 17 days (range, 1–205 days), with 40 children dying early (<1 day of PICU admission). The majority of nonsurvivors (83.9%) had comorbid illnesses. Children with early mortality were more likely to have neurological findings (62.5%), hypotension (82.5%), oliguria (47.5%), acidosis (92.5%), coagulopathy (30.0%), and cardiac arrest (45.0%) and less likely to have terminal illnesses (52.5%) and chronic illnesses (75.6%). Children who died early had a higher mean age (81.8 months) and Pediatric Risk of Mortality (PRISM) III score (37). In children who died early, the first three signs during ICU admission were hypoglycemia in 68.5%, neurological symptoms in 43.5%, and acidosis in 78.3%. Sixty-seven patients needed continuous renal replacement therapy, 51 required extracorporeal membrane oxygenation support, and 10 underwent extracorporeal cardiopulmonary resuscitation. Conclusions: We found that rates of neurological findings, hypotension, oliguria, acidosis, coagulation disorder, and cardiac arrest and PRISM III scores were higher in children who died early compared to those who died later.

10 August 2012 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
HTHakan Turan
Hakan Turan
MOMesut Okur
Mesut Okur
EKErtugrul Kaya
Ertugrul Kaya
EGemrah gün
emrah gün
CACihangir Aliagaoglu
Cihangir Aliagaoglu
It is highly popular among children and young adults to have temporary henna tattoos on their bodies in different colors and figures. Henna is a greenish natural powder obtained from the flowers and dry leaves of Lawsonia alba plant and its allergenicity is very low. Henna is also used in combination with other coloring substances such as para-phenylenediamine in order to darken the color and create a permanent tattoo effect. Para-phenylenediamine is a substance with high allergenicity potential and may cause serious allergic reactions. Here, we aimed to draw attention to the potential harms of para-phenylenediamine containing temporary tattoos by presenting a child patient who developed allergic contact dermatitis after having a scorpion-shaped temporary tattoo on his forearm.

1 March 2022 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
AÖAHMET GÖKCAN ÖZTÜRK
AHMET GÖKCAN ÖZTÜRK
ZKZeynep Erva Küçük
Zeynep Erva Küçük
SÖSerhan Özcan
Serhan Özcan
MHMERVE HAVAN
MERVE HAVAN
EGemrah gün
emrah gün
TKTANIL KENDIRLI
TANIL KENDIRLI
Objective: Therapeutic plasma exchange has been used as a primary or supportive treatment in many diseases in recent years and has achieved satisfactory results in lots of diseases in children. Therapeutic plasma exchange procedure is changing plasma component of a patient's blood with the new plasma as a replacement solution. The aim of this study is to share our experience of therapeutic plasma exchange on varying indications in critically ill children who were accepted to our pediatric intensive care unit. Materials and Methods: We conducted this study between December 2010 and February 2020, retrospectively. Patients’ data such as age, sex, indication, number of sessions, vascular access route, and type of replacement fluid used were obtained from medical records. Indications for therapeutic plasma exchange were classified according to the 2019 American Society for Apheresis categorization. The patient’s follow-up, clinical courses, therapeutic plasma exchange season count, complications, and outcome were evaluated according to each indications and their overall condition. Results: This study included a total of the 84 patients who underwent therapeutic plasma exchange, and their median (minimum-maximum) ages were 7.07 years (0.2-18), 57.1% were male (n = 48) and 42.9% were female (n = 36). A total of 463 sessions of therapeutic plasma exchange were performed in 84 patients. The most common indication was thrombocytopenia-associated multi-organ failure with sepsis (40.4%, n = 34) followed by liver failure/hepatic encephalopathy (28.5%, n = 24) and autoimmune encephalitis (9.5%, n = 8), and according to The American Society for Apheresis 2019 category, patients distributions were as follows: 15.4% of the patients were placed in category 1 (n = 13), 5.9% in category 2 (n = 5), 77.3% in category 3 (n = 65), and 1.1% in category 4 (n = 1). Therapeutic plasma exchange was combined to extracorporeal membrane oxygenation in 10 patients (11.9%) and continuous renal replacement therapies in 39 (46.4%) patients. Finally, the survival rate was 50% in all patients, and the lowest survival rate was 41.5% (n = 27) in category 3 group. Conclusion: Therapeutic plasma exchange is enlarging to varying indications and showing to be more effective on a lot of disorders in children. Also, it is available in pediatric age groups and in different states like combined with other extracorporeal therapies. Cite this article as: Gökcan Öztürk A, Erva Küçük Z, Özcan S, et al. Use of therapeutic plasma exchange in the pediatric intensive care unit. Turk Arch Pediatr. 2022;57(2):186-192.

25 February 2022 in The Turkish Journal of Pediatrics
Verified
Journal Article
Closed access
EGemrah gün
emrah gün
HÖHalil Özdemir
Halil Özdemir
DÇDilara Besli Çelik
Dilara Besli Çelik
EBEdin Botan
Edin Botan
TKTanıl Kendirli
Tanıl Kendirli
Background. Saccharomyces cerevisiae is one of the microorganisms commonly used as a probiotic. Although it is primarily known as non-pathogenic, it may cause fungemia, particularly in immunocompromised patients or children with a history of long-term hospital stay. Case. A 6-month-old boy with a history of ventriculostomy, ventriculoperitoneal shunt implantation, and external drainage due to an intracranial mass and hydrocephalus was admitted to the pediatric intensive care unit (PICU) on postoperative day 14 due to respiratory distress and intubated on admission. He was started on broad spectrum antibiotics on day 25 of the admission due to fever and clinical deterioration. Culture of the central venous catheter (CVC) yielded S. cerevisiae, the CVC was removed, and the patient was started on caspofungin. We noticed that a patient near this patient was on a probiotic preparation containing S. boulardii for diarrhea before PICU admission. His fever subsided on day 2 of caspofungin, and laboratory findings normalized on follow-up. Conclusions. Probiotics should not be used in PICUs because of the high risk for CVC-related sepsis in critically ill children.

1 August 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
EGemrah gün
emrah gün
ADAyşen Durak
Ayşen Durak
EBEdin Botan
Edin Botan
SPSelen Şimşek Pervane
Selen Şimşek Pervane
AGAnar Gurbanov
Anar Gurbanov
TKTANIL KENDIRLI
TANIL KENDIRLI
Background: The aim of this study is to determine the indication, timing, and administration of extracorporeal therapies such as total plasma exchange and continuous renal replacement therapy in children with acute liver failure or acute-on-chronic liver failure. Methods: This study is conducted as a retrospective, single-center study. Between January 2016 and December 2021, pediatric acute liver failure or acute-on-chronic liver failure patients for whom total plasma exchange and/or continuous renal replacement therapy was performed were included in this study. Results: Thirty-four children with acute liver failure or acute-on-chronic liver failure were included during the study period. The children comprised 14 (41.1%) males, and the median age of the patients was 54 months (5-21). Twenty-four patients (70.6%) had pediatric acute liver failure, and 10 patients (29.4%) had acute-on-chronic liver failure. Patients’ median model for end-stage liver disease and pediatric end-stage liver disease scores were 24.7/23.5, respectively. Total plasma exchange therapy was performed on all patients whereas continuous renal replacement therapy was performed on 13 patients (38.2%). The median duration of continuous renal replacement therapy was 2.5 days (2-24). The median number of the total plasma exchange sessions was 3 (1-20). The median length of stay in pediatric intensive care unit was 4.5 (2-74) days. Eleven (32.5%) patients had 1 or more improvements in hepatic encephalopathy scores after extracorporeal therapy. Eleven (32.5%) patients died. There was a significant difference between the survivors and non-survivors with respect to levels of albumin, ammonia, pediatric risk of mortality scores, and pre-hepatic encephalopathy scores. Liver transplantation was performed in 4 of 24 pediatric acute liver failure patients, and all of them survived. Conclusion: Total plasma exchange and continuous renal replacement therapy are life-saving, and both methods may reduce morbidity and mortality, also bridging to liver transplantation. Cite this article as: Gün E, Durak A, Botan E, et al. Extracorporeal therapies in children with acute liver failure: A single-center experience. Turk J Gastroenterol. 2023; 34(1): 73-79.